Head and Neck Carcinoma, Other — Trials

Head and Neck Carcinoma, Other — Trials · CancerIndex

Clinical trials

Registered studies

128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 35
Recruiting: 17
Ph III recruiting: 1
Growth YoY: —
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (14)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04760288	A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).(AcceleRET-MTC)	withdrawn	Phase 3	0	Hoffmann-La RocheINDUSTRY	1	Jan 5, 2024	clinicaltrials
NCT03838692	Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer	withdrawn	Phase 2	0	Antonio FojoOTHER	0	Oct 13, 2021	clinicaltrials